Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-02-27
2007-02-27
Oh, Taylor Victor (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C560S009000, C560S041000, C562S426000, C562S450000
Reexamination Certificate
active
10886927
ABSTRACT:
It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
REFERENCES:
patent: 4076841 (1978-02-01), Wagner et al.
patent: 5262439 (1993-11-01), Parthasarathy
patent: 5294724 (1994-03-01), Jendralla et al.
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5770355 (1998-06-01), Brocia
patent: 6121319 (2000-09-01), Somers
patent: 6147250 (2000-11-01), Somers
patent: 6323359 (2001-11-01), Jass
patent: 6448019 (2002-09-01), Mendelsohn et al.
patent: 6548699 (2003-04-01), Medford et al.
patent: 6602914 (2003-08-01), Meng
patent: 6617352 (2003-09-01), Somers
patent: 6670398 (2003-12-01), Edwards et al.
patent: 6881860 (2005-04-01), Luchoomun et al.
patent: 2002/0016300 (2002-02-01), Meng et al.
patent: 2002/0188118 (2002-12-01), Meng
patent: 2002/0193446 (2002-12-01), Meng
patent: 2003/0064967 (2003-04-01), Luchoomun et al.
patent: 0 212 310 (1987-03-01), None
patent: 0 254 272 (1988-01-01), None
patent: 0 292 660 (1988-11-01), None
patent: 0 348 203 (1989-12-01), None
patent: 0 418 648 (1991-03-01), None
patent: 2.130.975 (1972-11-01), None
patent: 2.133.024 (1972-11-01), None
patent: 2.134.810 (1972-12-01), None
patent: 2.140.769 (1973-01-01), None
patent: 2.168.137 (1973-08-01), None
patent: WO 95/30415 (1995-11-01), None
patent: WO 96/08239 (1996-03-01), None
patent: WO 97/26258 (1997-07-01), None
patent: WO 98/30255 (1998-07-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 98/51662 (1998-11-01), None
patent: WO 99/01118 (1999-01-01), None
patent: WO 99/24400 (1999-05-01), None
patent: WO 00/26184 (2000-05-01), None
patent: WO 00/28332 (2000-05-01), None
Combettes-Souverain, M. et al., “SR-B1 et métabolisme du cholesterol,”Médecine Sciences, 15(11):1252-1258 (Nov. 1999). Abstract XP 008001010.
Cominacini, L., et al., “Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells,”Free Radical Biol.&Med., 22(1/2): 117-127 (1997).
De Meglio, P., et al. New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity, Farmaco, Ed. Sci., 1985, 40(11), 833-844. In Italian; abstract provided in English:Chem Abstr.AN 1986:28675, DN 104:28675; & partial transl. in English. Abstract XP-002124424.
Feldman, D., et al., “The in vitro and ex vivo antioxidant properties and hypolipidemic activity of CGP 2881,”Atherosclerosis, 144:343-355 (Dec. 28, 1998).
Fruebis, J., et al., “A comparison of the antiatherogenic effects of probucol and of a structural analogure of probucol in low-density lipoprotein receptor-deficient rabbits,”J. Clinical Investigation, 94:392-398 (Jul. 1994).
Funke, H., et al., “Uptake of apolipoprotein E-containing high density lipoproteins by hepatic parenchymal cells,”Arteriosclerosis, 4(5):452-461 (Sep./Oct. 1984). Abstract XP-008001004.
Lankin, V.Z., et al.,Dokl. Akad. Nauk, 351(4):554-557.Chem. AbstractsDN 127:75973. Abstract XP-002115597.
Mao, S.J., et al., “Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits,”J. Med. Chem., 34(1):298-302 (Jan. 1991).
Mao, S.J., et al., “Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogure (MDL 29,311) that does not lower serum cholesterol,”Arteriosclerosis and Thrombosis, 11(5):1266-1275 (Sep./Oct. 1991).
Mata, P., et al., “Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation,”Atherosclerosis, 137:367-376 (1998). Abstract XP-001061299.
Meng, C.O., et al., “Novel phonolic antioxidants as multifunctional inhibitors of inducible VCAM-1 experssion for use in atherosclerosis,”Bioorganic&Medicinal Chemistry Letters, 12(18):2545-2548 (Sep. 16, 2002).
Miller, M., et al., “Apolipoprotein A-IZavalla (Leu159→ Pro) HDL cholesterol deficiency in a kindred associated with premature coronary artery disease,”Arterioscler Thromb. Vasc. Biol., 18(8):1242-1247 (Aug. 1998). Abstract XO-008001006.
Neuworth, M.B., et al. “Synthesis and hyopcholesterolemic activity of alkylidenedithio bisphenols,”J. Med. Chem., 13(4):722-725 (1970).Chem. AbstractsAN 1970:445047. Abstract XP-002124423.
Pfeuffer, M.A., et al., “Probucol increases the selective uptake of HDL cholesterol esters by Hep G2 human hepatoma cells,”Arteriosclerosis and Thrombosis, 12(7):870-878 (Jul. 1992). Abstract XP-008001007.
Ramasamy, S., et al., “Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells,”Molecular Pharmacology, 56:116-123 (Apr. 5, 1999).
Rinninger, F., et al. , “Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism”,Atherioschler. Throm. Vasc. Biol., 19(5):1325-1332 (May 1999).
Sawayama Y., et al., “Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia,”Journal of the American College of Cardiology, 39(4):610-616 (Feb. 20, 2002).
Luchoomun Jayraz
Meng Charles Q.
Saxena Uday
Sikorski James A.
Atherogenics, Inc.
King & Spalding
Oh Taylor Victor
LandOfFree
Compounds and methods to increase plasma HDL cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods to increase plasma HDL cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods to increase plasma HDL cholesterol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840789